Selected research
Industry Research
Inclusion Body Myositis Industry Research Report 2026
Market perspective
The global Inclusion Body Myositis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Inclusion Body Myositis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Inclusion Body Myositis is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Inclusion Body Myositis is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Inclusion Body Myositis include Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS and Ultragenyx Pharmaceutical Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Inclusion Body Myositis market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Inclusion Body Myositis Market by Company
Acceleron Pharma Inc
KPI Therapeutics Inc
Milo Biotechnology LLC
Nobelpharma Co Ltd
Orphazyme ApS
Ultragenyx Pharmaceutical Inc
Inclusion Body Myositis Segment by Type
ACE-083
Aceneuramic Acid ER
UX-007
UX-001P
ALZ-1903
Others
Inclusion Body Myositis Segment by Application
Research Center
Hospital
Clinic
Inclusion Body Myositis Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inclusion Body Myositis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inclusion Body Myositis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inclusion Body Myositis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Inclusion Body Myositis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Inclusion Body Myositis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Inclusion Body Myositis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ACE-083
- Aceneuramic Acid ER
- UX-007
- UX-001P
- ALZ-1903
- Others
Applications
- Research Center
- Hospital
- Clinic
Companies covered
- Acceleron Pharma Inc
- KPI Therapeutics Inc
- Milo Biotechnology LLC
- Nobelpharma Co Ltd
- Orphazyme ApS
- Ultragenyx Pharmaceutical Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Inclusion Body Myositis Market Size (2021-2032)
- 2.2.2 Global Inclusion Body Myositis Sales (2021-2032)
- 2.2.3 Global Inclusion Body Myositis Market Average Price (2021-2032)
- 2.3 Inclusion Body Myositis by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 ACE-083
- 2.3.3 Aceneuramic Acid ER
- 2.3.4 UX-007
- 2.3.5 UX-001P
- 2.3.6 ALZ-1903
- 2.3.7 Others
- 2.4 Inclusion Body Myositis by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Research Center
- 2.4.3 Hospital
- 2.4.4 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Inclusion Body Myositis Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Inclusion Body Myositis Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Inclusion Body Myositis Revenue of Manufacturers (2021-2026)
- 3.4 Global Inclusion Body Myositis Average Price by Manufacturers (2021-2026)
- 3.5 Global Inclusion Body Myositis Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Inclusion Body Myositis, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Inclusion Body Myositis, Product Type & Application
- 3.8 Global Manufacturers of Inclusion Body Myositis, Established Date
- 3.9 Global Inclusion Body Myositis Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Acceleron Pharma Inc
- 4.1.1 Acceleron Pharma Inc Company Information
- 4.1.2 Acceleron Pharma Inc Business Overview
- 4.1.3 Acceleron Pharma Inc Inclusion Body Myositis Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Acceleron Pharma Inc Inclusion Body Myositis Product Portfolio
- 4.1.5 Acceleron Pharma Inc Recent Developments
- 4.2 KPI Therapeutics Inc
- 4.2.1 KPI Therapeutics Inc Company Information
- 4.2.2 KPI Therapeutics Inc Business Overview
- 4.2.3 KPI Therapeutics Inc Inclusion Body Myositis Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 KPI Therapeutics Inc Inclusion Body Myositis Product Portfolio
- 4.2.5 KPI Therapeutics Inc Recent Developments
- 4.3 Milo Biotechnology LLC
- 4.3.1 Milo Biotechnology LLC Company Information
- 4.3.2 Milo Biotechnology LLC Business Overview
- 4.3.3 Milo Biotechnology LLC Inclusion Body Myositis Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Milo Biotechnology LLC Inclusion Body Myositis Product Portfolio
- 4.3.5 Milo Biotechnology LLC Recent Developments
- 4.4 Nobelpharma Co Ltd
- 4.4.1 Nobelpharma Co Ltd Company Information
- 4.4.2 Nobelpharma Co Ltd Business Overview
- 4.4.3 Nobelpharma Co Ltd Inclusion Body Myositis Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Nobelpharma Co Ltd Inclusion Body Myositis Product Portfolio
- 4.4.5 Nobelpharma Co Ltd Recent Developments
- 4.5 Orphazyme ApS
- 4.5.1 Orphazyme ApS Company Information
- 4.5.2 Orphazyme ApS Business Overview
- 4.5.3 Orphazyme ApS Inclusion Body Myositis Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Orphazyme ApS Inclusion Body Myositis Product Portfolio
- 4.5.5 Orphazyme ApS Recent Developments
- 4.6 Ultragenyx Pharmaceutical Inc
- 4.6.1 Ultragenyx Pharmaceutical Inc Company Information
- 4.6.2 Ultragenyx Pharmaceutical Inc Business Overview
- 4.6.3 Ultragenyx Pharmaceutical Inc Inclusion Body Myositis Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ultragenyx Pharmaceutical Inc Inclusion Body Myositis Product Portfolio
- 4.6.5 Ultragenyx Pharmaceutical Inc Recent Developments
5 Global Inclusion Body Myositis Market Scenario by Region
- 5.1 Global Inclusion Body Myositis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Inclusion Body Myositis Sales by Region: 2021-2032
- 5.2.1 Global Inclusion Body Myositis Sales by Region: 2021-2026
- 5.2.2 Global Inclusion Body Myositis Sales by Region: 2027-2032
- 5.3 Global Inclusion Body Myositis Revenue by Region: 2021-2032
- 5.3.1 Global Inclusion Body Myositis Revenue by Region: 2021-2026
- 5.3.2 Global Inclusion Body Myositis Revenue by Region: 2027-2032
- 5.4 North America Inclusion Body Myositis Market Facts & Figures by Country
- 5.4.1 North America Inclusion Body Myositis Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Inclusion Body Myositis Sales by Country (2021-2032)
- 5.4.3 North America Inclusion Body Myositis Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Inclusion Body Myositis Market Facts & Figures by Country
- 5.5.1 Europe Inclusion Body Myositis Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Inclusion Body Myositis Sales by Country (2021-2032)
- 5.5.3 Europe Inclusion Body Myositis Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Inclusion Body Myositis Market Facts & Figures by Country
- 5.6.1 Asia Pacific Inclusion Body Myositis Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Inclusion Body Myositis Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Inclusion Body Myositis Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Inclusion Body Myositis Market Facts & Figures by Country
- 5.7.1 South America Inclusion Body Myositis Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Inclusion Body Myositis Sales by Country (2021-2032)
- 5.7.3 South America Inclusion Body Myositis Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Inclusion Body Myositis Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Inclusion Body Myositis Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Inclusion Body Myositis Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Inclusion Body Myositis Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Inclusion Body Myositis Sales by Type (2021-2032)
- 6.1.1 Global Inclusion Body Myositis Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Inclusion Body Myositis Sales Market Share by Type (2021-2032)
- 6.2 Global Inclusion Body Myositis Revenue by Type (2021-2032)
- 6.2.1 Global Inclusion Body Myositis Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Inclusion Body Myositis Revenue Market Share by Type (2021-2032)
- 6.3 Global Inclusion Body Myositis Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Inclusion Body Myositis Sales by Application (2021-2032)
- 7.1.1 Global Inclusion Body Myositis Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Inclusion Body Myositis Sales Market Share by Application (2021-2032)
- 7.2 Global Inclusion Body Myositis Revenue by Application (2021-2032)
- 7.2.1 Global Inclusion Body Myositis Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Inclusion Body Myositis Revenue Market Share by Application (2021-2032)
- 7.3 Global Inclusion Body Myositis Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Inclusion Body Myositis Value Chain Analysis
- 8.1.1 Inclusion Body Myositis Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Inclusion Body Myositis Production Mode & Process
- 8.2 Inclusion Body Myositis Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Inclusion Body Myositis Distributors
- 8.2.3 Inclusion Body Myositis Customers
9 Global Inclusion Body Myositis Analyzing Market Dynamics
- 9.1 Inclusion Body Myositis Industry Trends
- 9.2 Inclusion Body Myositis Industry Drivers
- 9.3 Inclusion Body Myositis Industry Opportunities and Challenges
- 9.4 Inclusion Body Myositis Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst